Intravenous (IV) Compounding Robots Market Report 2026

The intravenous (IV) compounding robots market size has grown rapidly in recent years. It will grow from $0.51 billion in 2025 to $0.58 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to growing focus on medication safety in hospitals, increasing incidence of chemotherapy drug preparation, rising adoption of pharmacy automation systems, expansion of centralized hospital pharmacies, and growing need to reduce human compounding errors.

The intravenous (IV) compounding robots market size is expected to see rapid growth in the next few years. It will grow to $0.99 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing demand for safe hazardous drug handling, growing adoption of automated sterile compounding, rising investments in hospital automation infrastructure, expansion of oncology treatment centers, and a rise in the need for operational efficiency in pharmacy workflows. Major trends in the forecast period include technology-driven innovations in robotic drug compounding, advancements in artificial intelligence (AI)-enabled dose verification, developments in closed system transfer integration, rising research and development in precision pharmacy robotics, and innovation in real-time monitoring and quality assurance systems.

The rising number of pharmaceutical clinical trials is expected to drive the growth of the intravenous (IV) compounding robots market in the coming years. Pharmaceutical clinical trials are structured research studies carried out to assess the safety, effectiveness, and optimal dosing of new drugs or therapies in human participants. The growth in the number of pharmaceutical clinical trials is driven by increasing demand for innovative treatments to address complex and emerging health conditions. IV compounding robots support clinical trial activities by enabling precise and consistent preparation of investigational medications, thereby improving the safety and reliability of study outcomes. For example, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials initiated in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023. As a result, the growing number of pharmaceutical clinical trials is contributing to the expansion of the intravenous compounding robots market.

The expanding adoption of personalized medicine and complex infusion protocols is also expected to propel the growth of the intravenous (IV) compounding robots market going forward. Personalized medicine involves tailoring medical treatments, including drug selection and dosing, based on individual patient characteristics such as genetic profiles, biomarkers, and disease conditions. The growth of personalized medicine is fueled by the increasing approval and clinical use of targeted therapies that require highly customized intravenous dosing and preparation. IV compounding robots support personalized medicine by automating accurate drug preparation and individualized dosing of high-potency therapies, ensuring safety, precision, and consistency for patient-specific treatment regimens. For instance, in November 2025, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 18 new personalized medicines in 2024, representing more than 25% of all new drug approvals, following 20 approvals in 2023, many of which require individualized IV preparation. Consequently, the expanding use of personalized medicine and complex infusion protocols is driving the growth of the intravenous compounding robots market.

Major participants in the intravenous (IV) compounding robots market are focusing on the development of innovative central pharmacy dispensing robots to improve accuracy, safety, and efficiency in intravenous medication preparation, support personalized medicine, and minimize occupational exposure to high-potency and hazardous drugs. Central pharmacy dispensing robots are automated systems that store, retrieve, and dispense medications with high precision within hospital or pharmacy environments, reducing errors and enhancing workflow efficiency. For example, in October 2025, Ballad Health, a US-based healthcare organization, deployed three compounding robots in its central fill pharmacy at Bristol Regional Medical Center in Tennessee. The adoption of these robots enables Ballad Health to streamline workflows, shorten turnaround times for IV drug preparation, and support personalized treatment protocols, while also strengthening patient safety and regulatory compliance in the handling of hazardous medications.

Major companies operating in the intravenous (iv) compounding robots market are Becton Dickinson and Company, Baxa Corporation, Grifols Engineering S.A., IMA Life S.p.A., ICU Medical Inc., Syntegon Technology GmbH, Omnicell Inc., OPTIMA Pharma GmbH, Marchesini Group S.p.A., Romaco Group, Trasis S.A., APOTECA S.p.A., ARxIUM Inc., Health Robotics S.r.l., Steriline Robotics, PharmaSmart Robotics, iPharma Automation, Robotic Automation Systems, Pharma Automation Solutions, Aesynt Inc., Aseptio Technologies LLC.

North America was the largest region in the intravenous (IV) compounding robots market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) compounding robots market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous (iv) compounding robots market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the iv compounding robots market by increasing costs of imported robotic hardware, precision sensors, control systems, and dosing components. hospitals and oncology centers in north america and europe are most affected due to dependence on imported robotics, while asia-pacific faces export cost pressures on advanced systems. these tariffs are raising system acquisition costs and delaying procurement decisions. at the same time, they are supporting domestic robotics manufacturing, localized component sourcing, and regional innovation in automated compounding platforms.

The intravenous (IV) compounding robots involves the deployment of automated robotic systems that precisely prepare intravenous medications under sterile and controlled compounding conditions. The primary objective of these systems is to enhance medication safety, ensure accurate dosing, and improve operational efficiency while minimizing human error and the risk of contamination. In addition, IV compounding robots enable consistent drug preparation, greater workflow automation, and compliance with stringent pharmaceutical quality and regulatory standards.

The key components of intravenous (IV) compounding robots include hardware, software, and consumables. Hardware represents robotic systems that automate sterile medication preparation with precision and safety. Product categories include centralized and decentralized robots. Technologies include gravimetric, volumetric, and hybrid dosing systems. Applications include chemotherapy, parenteral nutrition, monoclonal antibody preparation, and others, across hospitals, oncology centers, compounding pharmacies, and others.

The intravenous (IV) compounding robots market consists of revenues earned by entities by providing products such as fully automated intravenous (IV) compounding robots, semi automated intravenous (IV) compounding systems, chemotherapy compounding robots, and sterile pharmacy robotic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The intravenous (IV) compounding robots market includes sales of robotic arms, sterile compounding enclosures, automated dispensing units, and integrated software for workflow management. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.